Annabel is now cancer-free with survival odds of 75%, but relapses of HRN have a “high mortality rate”, Ms Ashmore said.
“With this particular cancer, the risk of relapses is always there and it’s very hard to feel happy and safe,” she said.
The drug difluoromethylornithine (DFMO) was available in Australia and the USA, and had been “proven to reduce relapse and increase survival rates to 85%”, she added.
But DFMO needs to be administered within three months of the patient completing immunotherapy, which means Annabel needs it by November at the latest.
“It’s time critical and the NHS approval process won’t happen quick enough for [Annabel],” Ms Ashmore said.
RIYADH: Gulf Cooperation Council countries recorded the highest value of outward workers’ remittances globally in…
RIYADH: Two Mongolian saker falcons sold for a combined SR550,000 ($147,000) at the opening auction…
JEDDAH: Three Saudi universities have advanced in the Times Higher Education World University Rankings 2027,…
RIYADH: Members of Saudi Arabia’s Masam project removed 1,256 explosive devices from various regions of…
RIYADH: AlUla has added seven destination management companies to its Preferred DMC Program, expanding its…
RIYADH: The central banks of the UAE and Syria signed a memorandum of understanding on…